Plus Therapeutics, clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, announced that it has partnered with K2bio (Houston, Texas) to implement novel analysis for cerebrospinal fluid (CSF) tumor and molecular biomarkers for CNS cancers.
Initial clinical specimen
processing and testing will begin in Q1 2024 in the Company’s ongoing Phase 1
ReSPECT-LM trial of rhenium (186Re) obisbemeda in patients with
leptomeningeal metastases (LM). This trial is currently receiving grant funding
through The Cancer Prevention and Research Institute of Texas (CPRIT), which is
expected to partially cover the testing costs.
To read more please visit:
Source: Framatome